Trastuzumab exposure reduced H9c2 cell viability in a concentration-dependent manner, with a reported half-maximal inhibitory concentration, or IC50, of 1.21 micromolar. The researchers also tested L-carnitine at 5 millimolar. When the cells received the IC50 concentration of trastuzumab together with that concentration of L-carnitine, the combination produced the strongest reduction in measured cellular toxicity among the tested conditions. The supplied abstract does not provide the full set of treatment comparisons or detailed statistical analyses, so the size and significance of the effect cannot be assessed from the available report.

Biochemical measurements showed that trastuzumab elevated troponin I, creatine kinase-MB, acetyl-CoA carboxylase-2 and malonyl-CoA, while L-carnitine counteracted these increases. At the messenger-RNA level, trastuzumab reduced expression of AMPK-α2 and carnitine palmitoyltransferase-1B, abbreviated CPT1B. The combination of trastuzumab and L-carnitine counteracted those reductions. Trastuzumab also decreased ATP and ATG-5 levels, and the combination counteracted those decreases. These observations were obtained in a cultured-cell model and therefore characterize molecular and viability responses under experimental conditions rather than clinical outcomes.

Based on the measured results, the authors concluded that trastuzumab disturbed AMPK-α2 downstream signaling, reduced ATP production and interfered with autophagy-related measurements, while L-carnitine tempered these effects. The study was designed as a preliminary mechanistic investigation, not a clinical trial, and its authors emphasized that additional research is required. The evidence therefore supports the narrower conclusion that L-carnitine attenuated selected trastuzumab-associated changes in H9c2 cells; it does not show that supplementation would be safe or effective for protecting the human heart during trastuzumab treatment.

Subject of Research: L-carnitine attenuation of trastuzumab-induced AMPK, metabolic and viability changes in cardiac H9c2 cells

Article Title: Mechanistic attenuation by L-carnitine of trastuzumab-induced downregulation of adenosine monophosphate -activated protein kinase signal in cardiac H9c2 cells

Article References: Attia, Y. M., Osman, A.-M. M., Shash, E., Elgazzar, M., Sharaky, M., Alanazi, F. E., Sayed-Ahmed, M. M., & Karkeet, R. M. (2026). Mechanistic attenuation by L-carnitine of trastuzumab-induced downregulation of adenosine monophosphate -activated protein kinase signal in cardiac H9c2 cells. BMC Pharmacology and Toxicology, 27(1), Article 140. https://doi.org/10.1186/s40360-026-01235-8

Image Credits: AI Generated

DOI: 10.1186/s40360-026-01235-8

Keywords: L-carnitine, trastuzumab, cardiotoxicity, H9c2 cells, AMPK-α2, CPT1B, ATP, autophagy, cell viability, Mechanistic, attenuation, trastuzumab-induced

The preclinical experiment used 28 rats divided equally into four groups, with seven animals in each group. The control animals received neither doxorubicin nor hydroxytyrosol. A second group received hydroxytyrosol orally at 100 mg/kg/day for four weeks. The third group received a single 10 mg/kg dose of doxorubicin by intraperitoneal injection on day 1. The fourth group received the same doxorubicin dose followed by oral hydroxytyrosol at 100 mg/kg/day, beginning 24 hours after the injection. Researchers examined serum 8-OHdG levels, cardiac expression of ISM-1, PODXL, p-mTOR and p-AKT, and histopathological changes in heart tissue. The analysis focused on biochemical, molecular and microscopic outcomes in an animal model rather than the protective effects of hydroxytyrosol in patients receiving cancer chemotherapy.

Doxorubicin is an effective chemotherapeutic agent used for various malignancies, but its clinical use is limited by cardiotoxicity. In the doxorubicin-only group, investigators found significantly elevated cardiac expression of ISM-1, PODXL, p-mTOR and p-AKT compared with controls, with each comparison reported at p < 0.001. These animals also showed marked histopathological damage. Vacuolization, mononuclear cell infiltration, necrosis and fibrosis scores were all significantly higher than in the control group, again at p < 0.001. Serum 8-OHdG concentrations also increased in the doxorubicin group. The authors interpreted this pattern as evidence of oxidative stress, DNA damage and deterioration in cardiac tissue under the experimental conditions.

When hydroxytyrosol was administered after doxorubicin, p-mTOR and p-AKT expression in cardiac tissue was significantly lower than in the doxorubicin-only group. The combination also produced significant reductions in intracytoplasmic vacuolization, mononuclear cell infiltration and necrosis. Serum 8-OHdG levels fell significantly in the combined-treatment group relative to the doxorubicin group, indicating less oxidative DNA damage according to the study’s measurement. The researchers characterized the overall findings as modulation of ISM-1, PODXL, p-mTOR and p-AKT expression, together with attenuation of tissue injury. The reduction in fibrosis did not reach statistical significance, with p = 0.590, so the results do not support a claim that hydroxytyrosol definitively reversed this component of cardiac injury.

These results indicate that hydroxytyrosol may influence molecular and biochemical pathways associated with doxorubicin toxicity in rat heart tissue. The treatment was associated with lower 8-OHdG concentrations, reduced p-mTOR and p-AKT expression, and improvement in several—but not all—measures of microscopic cardiac injury after a single doxorubicin dose. The experiment does not establish that hydroxytyrosol prevents cardiotoxicity in patients, preserves heart function, improves cancer-treatment outcomes or offers a substitute for established monitoring and treatment practices. The authors identified the limited sample size, the absence of cardiac functional assessment and the need for further studies as key limitations. Accordingly, the findings represent controlled laboratory evidence from 28 rats: hydroxytyrosol mitigated several measured indicators of doxorubicin-associated cardiac injury, while the reduction in fibrosis remained statistically uncertain.

Subject of Research: Effects of hydroxytyrosol on biochemical, molecular and histopathological markers of doxorubicin-associated cardiac injury in a rat model

Article Title: Effects of hydroxytyrosol on ISM-1, PODXL, p-mTOR, and p-AKT protein expression and 8-OHdG levels in doxorubicin-associated cardiac injury

Article References: Erdoğan, M. M., Kocaman, N., Onat, E., Erdoğdu, H., & Özdem, B. (2026). Effects of hydroxytyrosol on ISM-1, PODXL, p-mTOR, and p-AKT protein expression and 8-OHdG levels in doxorubicin-associated cardiac injury. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-026-05646-2

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05646-2

Keywords: hydroxytyrosol, doxorubicin, cardiotoxicity, cardiac injury, oxidative DNA damage, 8-OHdG, p-mTOR, p-AKT, rat model, olive oil polyphenol, Effects, ISM-1

Anthracyclines, including doxorubicin and epirubicin, are among the most effective chemotherapy agents available for breast cancer, but they carry a well-documented risk of cardiotoxicity. These drugs interfere with topoisomerase II and generate reactive oxygen species within cardiac mitochondria, leading to progressive myocyte injury, cell death, and ultimately a decline in left ventricular function. Cancer therapy-related cardiac dysfunction, abbreviated CTRCD, can manifest during treatment or emerge years later, significantly increasing cardiovascular morbidity and mortality among cancer survivors. Because breast cancer patients frequently receive anthracycline regimens and often live decades beyond their diagnosis, preventing even subtle early cardiac damage has become a central goal of cardio-oncology care.

Exercise has emerged as a candidate intervention precisely because it counteracts several of the mechanisms through which anthracyclines injure the heart. Preclinical research suggests that regular physical activity improves mitochondrial function, enhances antioxidant defenses, and promotes angiogenesis, all of which may buffer cardiomyocytes against chemotherapy-induced stress. Clinical guidelines from the European Society of Cardiology on cardio-oncology acknowledge the theoretical rationale for exercise-based cardioprotection, yet previous reviews have largely examined heterogeneous cancer populations receiving varied treatments, making it difficult to isolate the specific effect of exercise on anthracycline-induced cardiac dysfunction in breast cancer patients. The Spanish research team set out to close that gap with a rigorously focused analysis.

To do so, the investigators conducted a comprehensive search of PubMed, Scopus, the Cochrane Central Register of Controlled Trials, and Web of Science. They applied strict eligibility criteria: studies had to be randomized controlled trials including breast cancer patients undergoing anthracycline-based chemotherapy, the exercise intervention had to last at least twelve weeks with at least one session per week, and each trial had to report at least one of five prespecified outcomes. Those outcomes were left ventricular ejection fraction, global longitudinal strain, cardiac troponin I, cardiac troponin T, and N-terminal prohormone of brain natriuretic peptide, commonly known as NT-proBNP. Together, these markers capture different dimensions of cardiac injury, from pumping capacity and myocardial deformation to biochemical evidence of myocyte damage and neurohormonal activation.

After screening and quality assessment, six randomized controlled trials totaling 360 participants met the inclusion criteria. The meta-analysis revealed that exercise significantly attenuated the elevation of cardiac troponin I compared with usual cancer care, with a standardized mean difference of −0.50 and a 95 percent confidence interval spanning −0.93 to −0.06, yielding a p value of 0.02. Cardiac troponin I is a protein released when heart muscle cells are injured, and elevated levels during chemotherapy are among the earliest biochemical indicators of myocardial damage. The fact that exercising patients showed measurably lower troponin I elevations suggests that physical training may genuinely reduce the degree of acute myocyte injury caused by anthracyclines, rather than merely masking symptoms after damage has occurred.

However, the picture becomes more complicated when the other outcomes are considered. The analysis found no statistically significant between-group differences for left ventricular ejection fraction, the standard echocardiographic measure of pumping efficiency; for global longitudinal strain, a more sensitive deformation-based imaging metric; for cardiac troponin T, a related but structurally distinct isoform; or for NT-proBNP, a hormone released when the heart is under hemodynamic stress. This pattern is intriguing from a mechanistic standpoint. Troponin I reflects early cellular injury, whereas ejection fraction and strain measure functional consequences that may take longer to develop or may require larger sample sizes to detect reliably. It is possible that exercise protects cardiomyocytes at the biochemical level before those protective effects translate into measurable preservation of pump function, but the current evidence cannot confirm that sequence.

The authors are careful to frame their conclusion appropriately. They state that the cardioprotective role of exercise during anthracycline treatment remains uncertain, though the attenuation of cardiac troponin I elevation suggests a potential protective signal warranting further investigation. This nuanced position reflects the realities of the underlying evidence base. Six trials with 360 participants is a modest foundation for meta-analysis, and the individual studies varied in exercise modality, intensity, duration, and supervision. Some trials employed supervised aerobic training, others combined aerobic and resistance elements, and the timing of assessments relative to chemotherapy cycles differed across studies. Such heterogeneity, even among trials meeting strict inclusion criteria, can dilute true effects and widen confidence intervals.

The broader context of cardio-oncology research reinforces both the promise and the limitations of these findings. Earlier systematic reviews, including work by Zhang and colleagues in 2025 and Murray and colleagues in 2022, have generally reported favorable trends for exercise on cardiac outcomes in breast cancer patients, but they too have been constrained by small sample sizes and inconsistent outcome definitions. The European Society of Cardiology guidelines published in 2022 established biomarker criteria for diagnosing CTRCD, and subsequent research by Mecinaj and colleagues in 2024 demonstrated that applying those criteria changes the apparent incidence of cardiac dysfunction in treated populations. Standardization of both imaging and biomarker endpoints remains an unfinished project, and until it is completed, meta-analyses will continue to grapple with heterogeneous data.

What makes the current study particularly valuable is its exclusive focus on anthracycline-treated breast cancer patients, a population in which the cardiotoxic insult is relatively well characterized and the therapeutic window for intervention is clearly defined. By restricting inclusion to trials with interventions lasting at least twelve weeks and comparing exercise against usual cancer care, the Spanish team reduced some sources of noise that have plagued earlier reviews. The finding that troponin I, arguably the most mechanistically proximal biomarker of anthracycline injury, responded to exercise while more distal functional measures did not is biologically plausible and consistent with the understanding that subcellular damage precedes overt systolic dysfunction, sometimes by years.

Looking forward, the authors call for larger, standardized trials employing advanced assessment modalities and longer follow-up periods. Techniques such as stress echocardiography, cardiac magnetic resonance imaging with T1 mapping, and high-sensitivity troponin assays could detect subtler degrees of myocardial injury and dysfunction than conventional resting echocardiography. Longer follow-up is equally critical, because anthracycline cardiotoxicity can progress insidiously over a decade or more after exposure. Meanwhile, the ICOS-CORE working group, an international collaboration focused on cardio-oncology rehabilitation and exercise, published evidence priorities in 2025 aimed at establishing research standards for the field, signaling growing momentum behind precisely the kind of rigorous investigation this meta-analysis advocates. For now, breast cancer patients receiving anthracyclines should discuss exercise with their oncology and cardiology teams, balancing the encouraging troponin I signal against the honest uncertainty that still surrounds exercise as a proven cardioprotective therapy.

Subject of Research: Exercise training as a cardioprotective intervention against anthracycline-induced cardiac dysfunction in breast cancer patients

Article Title: Exercise for the mitigation of cancer therapy-related cardiac dysfunction in breast cancer patients treated with anthracyclines: a systematic review and meta-analysis

Article References: Marín, A. J., García-Coll, M. V., Moraleda, E. M., Castellanos-Montealegre, M., & Laín, S. A. (2026). Exercise for the mitigation of cancer therapy-related cardiac dysfunction in breast cancer patients treated with anthracyclines: a systematic review and meta-analysis. Supportive Care in Cancer, 34(10), Article 928. https://doi.org/10.1007/s00520-026-11085-z

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11085-z

Keywords: breast cancer, anthracyclines, cardiotoxicity, exercise, cardiac troponin I, cancer therapy-related cardiac dysfunction, cardio-oncology, meta-analysis, left ventricular ejection fraction, global longitudinal strain, NT-proBNP, chemotherapy

The scientific case rests on a remarkable convergence of biological properties. Zebrafish embryos develop outside the mother, with most organs forming within 24 hours of fertilization, and remain optically transparent for the first few days of life. This allows researchers to watch organogenesis, tumor growth, immune cell migration, and cardiac function unfold in real time inside a living vertebrate. A single breeding pair produces hundreds of eggs per week, fish reach sexual maturity in roughly three months, and maintenance costs are a fraction of those for mammalian colonies. Crucially, around 80 percent of human disease-linked genes have zebrafish orthologs, and core molecular processes—signal transduction, endocrine regulation, immune responses, and xenobiotic metabolism—are highly conserved, including functional counterparts of key drug-metabolizing enzymes and transporters. Modern genome-editing tools such as CRISPR/Cas9, Cre-lox systems, and transgenesis have all been adapted for the fish, enabling precise disease modelling and high-throughput in vivo screening at a scale unattainable in rodents.

The ethical architecture of the recommendations is anchored in the 3Rs framework of Replacement, Reduction, and Refinement, now extended by proposals for a fourth R, Responsibility, and a fifth R, Rehoming. The Society specifically recommends using embryos and larvae up to the stage preceding independent feeding—commonly around five days post-fertilization—for in vivo experiments. This timing matters legally as much as ethically: EU Directive 2010/63/EU defines its scope of protection with reference to independently feeding larval forms, meaning zebrafish embryos and early larvae fall outside the Directive’s formal scope. Polish national legislation, through the Act of 15 January 2015 on the protection of animals used for scientific or educational purposes, mirrors this exclusion. In practical terms, experiments on zebrafish embryos and early larvae may constitute a genuine legal alternative to classical protected-stage experiments, contributing to the replacement or reduction of mammalian models where scientifically appropriate. When later developmental stages or adult fish are required, the Society insists on approval from the competent Local Ethics Committee for Animal Experiments.

Nowhere is the model’s power more vivid than in oncology. The Society recommends the human-zebrafish xenograft approach, in which human cancer cells—from established lines or directly from patients—are implanted into zebrafish embryos or larvae. Because the larval immune system is not yet fully functional during the first days of life, human cells engraft and proliferate without immunosuppression. The transparent body permits direct visualization of tumor development, angiogenesis, and metastasis at single-cell resolution, and unlike in mouse models, human cancer cells in zebrafish readily migrate and form metastases, allowing drug effects on this critical aspect of tumor biology to be assessed under true in vivo conditions. Xenograft experiments can be completed in less than a week, whereas analogous mouse studies typically require several weeks. This so-called Avatar strategy is already entering clinical contexts: in a translational study involving breast cancer patients, complete concordance was demonstrated between chemotherapy responses observed in the larval model and the actual clinical responses, confirming high predictive value for personalized medicine. The model has also delivered clinically validated drugs—larval zebrafish studies revealed thalidomide’s strong inhibitory effect on tumor angiogenesis through suppression of VEGF signaling, helping establish thalidomide and its derivatives as therapies for neovascularization-dependent cancers such as multiple myeloma.

In toxicology, the recommendations position zebrafish as a tiered pre-filter for chemical and pharmaceutical safety. The Fish Embryo Acute Toxicity Test, standardized under OECD TG 236, determines lethal concentration values over a 96-hour exposure window in embryos, providing early hazard identification without adult vertebrates. While LC50 endpoints are not directly equivalent to rodent LD50 values, they deliver comparable information on acute toxicity and are primarily used for screening and prioritization rather than direct regulatory substitution. Embryonic transparency enables direct observation of teratogenic and embryotoxic potential, revealing morphological abnormalities, oxidative stress, apoptosis, and endocrine disruption induced by pharmaceuticals or contaminants. The assay’s compatibility with multi-well plate formats, robotic microscopes, computerized readers, and artificial intelligence allows automated detection of embryo orientation and organ-specific analysis of the heart, brain, or vessels. Regulatory recognition is growing: the FET assay is incorporated into OECD guidelines as an accepted alternative for chemical safety assessment, the US Food and Drug Administration acknowledges zebrafish for investigative and early-screening preclinical procedures, and the European Medicines Agency has expressed strong interest in preliminary regulatory reviews. The Society cautions, however, that zebrafish should not be regarded as a universal replacement where regulatory frameworks demand mammalian data on pregnancy, lactation, multigenerational endpoints, or long-term systemic organ toxicity.

Neurology and neuropsychiatry showcase the model’s translational depth. Zebrafish possess a hypothalamic–pituitary–interrenal axis homologous to the mammalian stress axis, with conserved cortisol synthesis, alongside well-organized serotonergic, dopaminergic, glutamatergic, and GABAergic neurotransmitter systems. Epilepsy research has been transformed by two complementary approaches: seizures can be induced in larvae with pentylenetetrazole, and genetic models based on the scn1lab gene—which corresponds to the human SCN1A gene mutated in Dravet syndrome—faithfully recapitulate reduced GABAergic signaling, spontaneous seizures, and abnormal neuronal activity. High-throughput phenotypic screening in multi-well formats using automated locomotor tracking and local field potential recordings identified clemizole as a potent seizure suppressor in the scn1lab model, and the same pipeline has highlighted serotonergic modulators such as fenfluramine and unexpected compound classes including synthetic cannabinoids. Classical antidepressants like fluoxetine and citalopram induce behavioral effects in zebrafish consistent with their human actions, and standardized larval assays—open-field thigmotaxis, light–dark preference, and light–dark challenge tests—quantify anxiety-like behavior with high predictive value. Social behavior assays in older larvae and juveniles have even been applied to model neurodevelopmental conditions relevant to autism spectrum disorders.

Metabolic disease research exploits the model’s conserved endocrine machinery. Zebrafish retain homologous insulin, glucagon, nuclear receptors, and appetite-regulating pathways; more than 70 percent of carbohydrate and glucose metabolic genes are conserved across zebrafish, frog, chicken, mouse, and human, with 57 percent linked to human type 2 diabetes. Larval insulin resistance models generated through elevated glucose, dexamethasone, or exogenous insulin exposure display features of impaired glucose handling suitable for evaluating antidiabetic drug candidates. For type 1 diabetes, transgenic lines expressing nitroreductase under the insulin promoter enable inducible, highly specific beta cell destruction upon metronidazole exposure, producing reproducible insulin deficiency and hyperglycemia while allowing real-time visualization of pancreatic islet regeneration. Adult fish on high-fat or high-cholesterol diets develop obesity, dyslipidemia, and atherosclerosis-like vascular lipid accumulation with conserved lipoprotein metabolism and inflammatory pathways. Storage diseases are equally tractable: the zebrafish model of Fabry disease, lacking alpha-galactosidase A activity, revealed an independent mechanism of kidney damage driven by mitochondrial alterations and disturbed glycolysis and galactose metabolism, beyond the canonical lysosomal accumulation of globotriaosylceramide.

Immunology and cardiology round out the model’s portfolio with distinctive technical advantages. During the first week of life, zebrafish larvae possess only a functional innate immune system, with adaptive immunity developing weeks later—a temporal separation that permits selective investigation of neutrophil and macrophage responses without adaptive interference. Transgenic reporter lines such as Tg(mpx:GFP) for neutrophils and Tg(mpeg1:mCherry) for macrophages enable direct visualization of leukocyte migration and host–pathogen interactions in living organisms. Infection of larvae with Mycobacterium marinum, closely related to Mycobacterium tuberculosis, recapitulates the hallmark organized granulomas of human tuberculosis and has enabled identification of virulence factors, host defense mechanisms, and high-throughput screening for novel antitubercular drugs, while reporter lines tracking autophagy marker LC3 recruitment to bacterial vacuoles illuminate cell-autonomous immunity against Staphylococcus aureus and Salmonella Typhimurium. In cardiology, homologs of key cardiac ion channels including hERG make zebrafish respond to QT-prolonging drugs comparably to humans: a landmark study identified 22 of 23 clinically relevant proarrhythmic compounds as positive in the assay, a drug-sensitized screen uncovered 15 genes affecting cardiac repolarization including GINS3, and screening of 3,000 compounds in a doxorubicin-induced cardiomyopathy model yielded the cardioprotective molecules visnagin and diphenylurea, subsequently validated in mice. Adult zebrafish uniquely regenerate cardiac muscle after injury through cardiomyocyte dedifferentiation and proliferation—a capacity absent in mammals—making the fish an unmatched system for heart regeneration research.

The recommendations arrive against a sobering backdrop of preclinical failure. The overall preclinical-to-market attrition rate exceeds 92 percent, a figure unchanged for three decades. Mouse models produce positive preclinical results in 90 to 95 percent of studies, yet fewer than 8 to 10 percent translate to approved drugs, falling to 3.5 percent in oncology—a gap attributed less to mouse biology than to study design, publication bias, sex bias, lack of genetic diversity, and failure to reproduce the full complexity of human immunology and metabolism. Notably, zebrafish under 120 hours post-fertilization, which do not swim or feed independently, are considered New Alternative Methodologies under EU Directive 2010/63, and the FDA has developed a draft on NAM use in preclinical research paving the way for zebrafish in these studies. The Society frames the fish as the most productive early-stage preclinical pipeline: an intermediate platform positioned between simple in vitro systems and resource-intensive mammalian studies, used to prioritize compounds, identify early toxicity signals, and refine hypotheses before mammalian validation. Implementation, the authors stress, requires question-driven design, standardized protocols with defined developmental stages, exposure windows, and controls, robust biologically relevant endpoints, and predefined criteria for progression to mammalian models. With zebrafish now the second most frequently used animal model in EU research after mice, the Society calls on research institutions, pharmaceutical companies, and regulatory agencies to systematically incorporate these embryo and larval assays into efficacy and safety evaluation, grant applications, and research standards—an integration the authors argue will yield more humane, efficient, and innovative science, ultimately benefiting medical progress and public health.

Subject of Research: Use of the zebrafish (Danio rerio) model in biomedical research and its recommendations for replacing mammalian models

Article Title: Recommendations of the Polish Zebrafish Society on the use of the zebrafish (Danio rerio) model in biomedical research

Article References: Podlasz, P., Migocka-Patrzałek, M., Prajsnar, T. K., Sarosiak, A., & Tylzanowski, P. (2026). Recommendations of the Polish Zebrafish Society on the use of the zebrafish (Danio rerio) model in biomedical research. Acta Biochimica Polonica, 73, Article 16545. https://doi.org/10.3389/abp.2026.16545

Image Credits: AI Generated

DOI: 10.3389/abp.2026.16545

Keywords: zebrafish, Danio rerio, 3Rs principles, preclinical research, drug discovery, toxicology, oncology, xenograft, cardiotoxicity, epilepsy, diabetes, immunology

The clinical stakes are enormous. Up to a quarter of patients treated with doxorubicin develop cardiac injury during or after therapy, ranging from silent myocardial damage to full-blown congestive heart failure. The risk climbs steeply with cumulative dose: at 400 mg/m² the incidence of heart failure hovers around 5 percent, but it jumps to roughly 26 percent at 550 mg/m² and a staggering 48 percent at 700 mg/m². Dexrazoxane remains the only FDA-approved cardioprotective agent, yet concerns about whether it might blunt doxorubicin’s anticancer power have limited its use. Beta-blockers and other supportive measures help some patients, but none directly address the fundamental breakdown in cellular housekeeping that Tian and colleagues identify as central to the disease.

To understand why the heart is so vulnerable, one must appreciate its cellular architecture. Cardiomyocytes are packed with mitochondria — the power plants that fuel continuous contraction — and with the sarcoplasmic reticulum, a specialized endoplasmic reticulum that stores and releases the calcium ions triggering each heartbeat. Doxorubicin attacks both. It intercalates into DNA and traps topoisomerase IIβ in lethal cleavage complexes, generating persistent double-strand breaks. Simultaneously, it disrupts iron metabolism and drives redox cycling, flooding cells with reactive oxygen species. The mitochondria swell, their cristae collapse, and their DNA mutates. The ER loses its ability to fold proteins properly and to buffer calcium. These twin injuries converge on the same problem: the cell’s recycling systems must somehow keep pace with escalating damage.

Mitophagy is the cell’s way of selectively devouring broken mitochondria. When a mitochondrion loses its membrane potential, a protein called PINK1 accumulates on its outer surface and recruits Parkin, which tags the organelle with ubiquitin chains that autophagy receptors like p62 and optineurin recognize. Alternatively, receptor proteins such as BNIP3, NIX, and FUNDC1 can bind LC3 directly on forming autophagosomes, bypassing the ubiquitin step entirely. Either route ends with the damaged mitochondrion sealed inside an autophagosome, fused with a lysosome, and digested. But here is where the review delivers its most provocative insight: doxorubicin does not simply switch mitophagy on or off. Instead, it disrupts the process at multiple checkpoints — damage sensing, cargo labeling, autophagosome formation, and lysosomal degradation — and the outcome depends entirely on which checkpoint fails first.

The authors marshal evidence from dozens of preclinical studies to build this checkpoint-dependent framework. In some models, low doses of doxorubicin trigger a compensatory mitophagy response that genuinely protects the heart by clearing damaged mitochondria before they accumulate. In others, the drug drives excessive mitochondrial fragmentation through the fission protein DRP1, creating a feed-forward loop in which Parkin recruitment accelerates fission, which in turn generates more fragments for mitophagy to consume — eventually depleting the cell’s mitochondrial reserve faster than it can be replaced. Still other studies reveal a third failure mode: cytosolic p53, elevated by doxorubicin, binds Parkin and prevents it from reaching mitochondria, starving the pathway at its very first step. And in models where flux has been directly measured, autophagosomes pile up because the final fusion with lysosomes never happens, leaving damaged organelles stranded inside cellular garbage bags that never get emptied.

What makes this framework so powerful is that it explains decades of apparently contradictory findings. Studies reporting that doxorubicin

The apparent contradictions in the literature become even more tractable when one considers how experimental design shapes what investigators observe. The review emphasizes that discrepancies among studies reporting protective organelle clearance, insufficient autophagy initiation, or stalled degradation may reflect differences in doxorubicin dose, exposure duration, and exposure pattern, as well as the choice of experimental model and whether autophagic flux was actually measured rather than inferred. A single time point showing abundant autophagosomes, for instance, could indicate either vigorous recycling or a jammed disposal system; only dynamic flux assays can distinguish between these possibilities. Many earlier studies relied on static markers such as LC3-II abundance or puncta formation, which cannot by themselves reveal whether cargo ultimately reaches the lysosome. This methodological blind spot may account for a substantial fraction of the conflicting conclusions that have accumulated over the years, and it underscores the review’s call for standardized flux assessment in future work.

ER-phagy, the selective degradation of endoplasmic reticulum through autophagy, receives comparatively less experimental attention in the doxorubicin setting, and the authors are careful to frame the available evidence cautiously. Receptor proteins such as FAM134B, RTN3, ATL3, and TEX264 can each recognize stressed or damaged ER fragments and deliver them to autophagosomes, but the specific contributions of these receptors in cardiomyocytes exposed to anthracyclines remain incompletely mapped. Existing studies differ in the doxorubicin regimens employed, the receptor pathways interrogated, and the rigor of flux measurement, making direct comparison difficult. The review therefore proposes functional divergence of ER-phagy as an interpretive framework rather than a settled conclusion: in some contexts ER-phagy may relieve stress by clearing misfolded protein aggregates and damaged reticular membranes, while in others it may strip the cell of calcium-handling capacity at the sarcoplasmic reticulum, worsening contractile dysfunction. Disentangling these possibilities will require receptor-specific tools and longitudinal designs that current literature largely lacks.

A further layer of complexity arises from the physical intimacy of the two organelles. Mitochondria-associated ER membranes, or MAMs, are contact sites where the ER and mitochondria lie within tens of nanometers of each other, tethered by protein complexes that coordinate calcium transfer, mitochondrial dynamics, and stress signaling. In healthy cardiomyocytes, these junctions allow efficient shuttling of calcium ions from the sarcoplasmic reticulum into mitochondria to match energy production with contractile demand. Doxorubicin disrupts this architecture, and the review argues that MAM dysfunction may serve as the mechanistic hinge connecting mitochondrial injury, ER stress, and selective autophagy imbalance. Receptors involved in mitophagy and ER-phagy localize at or near these contact sites, and autophagosome formation itself can be coordinated there. If MAM integrity deteriorates, calcium mishandling, energetic failure, and defective organelle quality control may reinforce one another, producing a vicious cycle that no single-pathway intervention is likely to break.

When mitochondrial clearance fails, the consequences extend beyond energy depletion. Damaged mitochondria that persist within cardiomyocytes can leak mitochondrial DNA into the cytosol and release mitochondrial reactive oxygen species, both of which activate inflammatory signaling through the cGAS-STING pathway and the NLRP3 inflammasome. This places mitophagy at the interface between organelle quality control and innate immunity, suggesting that failed clearance may convert a purely metabolic injury into a sterile inflammatory process that accelerates myocardial damage. Such a mechanism could help explain why cardiac injury after doxorubicin sometimes progresses long after the drug has been cleared from the body, and why late-onset cardiotoxicity, with a reported mean latency of approximately seven years, remains so difficult to predict or prevent.

The temporal dimension of doxorubicin-induced cardiotoxicity adds another consideration for translational efforts. Acute injury occurring within hours to days of exposure is often at least partly reversible and involves vacuolar change, interstitial edema, and inflammatory infiltration. Early-onset chronic disease emerges within a year and represents the most common clinically relevant pattern, evolving from subclinical dysfunction toward overt heart failure. Late-onset disease can surface years or even decades later, with restrictive cardiomyopathy appearing relatively more frequently and reflecting progressive fibrosis and myofibrillar disorganization following cardiomyocyte death. Because the dominant injury mechanisms and the state of the autophagy machinery likely differ across these phases, a cardioprotective strategy effective during acute exposure may prove useless or even harmful when applied years afterward. Stage-specific targeting of mitophagy and ER-phagy therefore emerges as a central theme of the review.

Subtle structural changes may also serve as early warning signs that current monitoring overlooks. Reductions in left ventricular mass have been observed after doxorubicin exposure in both experimental models and clinical cohorts, and this change can precede any measurable decline in ejection fraction while persisting for at least six months. Such remodeling suggests that functional indices alone capture the injury process late. Combination regimens modify the phenotype further: doxorubicin plus trastuzumab has been associated with reduced cardiac mass and biventricular dysfunction even without severe metabolic abnormalities or very high cumulative anthracycline exposure, and prior anthracycline treatment appears to increase susceptibility to trastuzumab-related cardiotoxicity, possibly through overlapping disruption of mitochondrial quality control.

The review is candid about the limits of the evidence base. Most of what is known about mitophagy and ER-phagy in this setting derives from cell culture and animal studies, and direct evidence from human myocardial tissue is essentially absent. The metformin experience offers a cautionary lesson: in a randomized trial, metformin preserved peripheral mitochondrial respiration to some extent yet failed to demonstrate clear cardiac benefit, implying that biologically plausible interventions may falter when cardiac target engagement is never confirmed. Peripheral surrogate markers, in other words, may not faithfully reflect what is happening inside the myocardium. Any future therapy built on modulating selective autophagy will need pharmacodynamic readouts drawn from cardiac tissue itself, together with careful attention to dose, timing, and the checkpoint at which the pathway has failed. Until such tools exist, the checkpoint framework offered by Tian and colleagues serves less as a treatment manual than as a map of where the search should concentrate.

Subject of Research: Selective autophagy mechanisms in doxorubicin-induced cardiotoxicity

Article Title: Mitophagy and ER-phagy in doxorubicin-induced cardiotoxicity: mechanisms, crosstalk, and therapeutic implications

Article References: Tian, Y., Chang, A., Guo, Z., Zhou, H., Chang, X., & Wu, J. (2026). Mitophagy and ER-phagy in doxorubicin-induced cardiotoxicity: mechanisms, crosstalk, and therapeutic implications. Journal of Advanced Research. https://doi.org/10.1016/j.jare.2026.10.022

Image Credits: AI Generated

DOI: 10.1016/j.jare.2026.10.022

Keywords: doxorubicin, cardiotoxicity, mitophagy, ER-phagy, autophagy, cardio-oncology, heart failure, chemotherapy, doxorubicin-induced, mechanisms, crosstalk, therapeutic

The central idea behind ultrasound-responsive drug delivery is elegantly simple. Microbubbles are gas-filled, shell-stabilized particles a few micrometers in diameter, originally developed as contrast agents for diagnostic imaging. When exposed to ultrasound waves, the encapsulated gas oscillates and eventually collapses through a phenomenon known as acoustic cavitation. If drug molecules are loaded into or onto the bubble shell, that collapse can eject or liberate the payload locally, creating a sharp temporal and spatial switch for drug release. In principle, a clinician could focus the ultrasound beam on a tumor and release the drug only within that volume, leaving healthy tissue—including the heart—largely unexposed to free cytotoxic agent.

What has often undermined this concept in practice is the way such formulations are developed. Traditional formulation work tends to proceed by trial and error, adjusting one variable at a time and hoping to stumble upon an acceptable product. The research team, led by Sonal Solanki and Nikunj Solanki together with collaborators across multiple Indian institutions, instead applied Quality by Design, or QbD, a systematic paradigm borrowed from pharmaceutical manufacturing science. QbD begins by defining a Quality Target Product Profile—the attributes the final product must possess—and then identifies critical quality attributes and the process and formulation parameters that control them. The result is a mathematical map relating input variables to product performance, allowing the formulator to operate deliberately within a proven design space rather than relying on luck.

Three formulation variables were selected as the critical factors to study: the concentration of chitosan, a biocompatible polysaccharide that forms the bubble shell; the concentration of palmitic acid, a fatty acid that likely stiffens and stabilizes the shell; and the concentration of Pluronic F68, a triblock copolymer surfactant widely used to modulate surface properties and stabilize emulsions. To explore how these three inputs interact, the team employed a Box–Behnken design, a response surface methodology that efficiently samples the experimental landscape with a manageable number of runs while allowing estimation of both main effects and quadratic interactions. The responses being optimized were microbubble size, doxorubicin encapsulation efficiency, and the burst release behavior triggered by ultrasound exposure.

The optimized formulation that emerged from the design space is notable for how tightly it threads the competing requirements. The microbubbles measure approximately 3.2 micrometers in diameter, small enough to behave well in vascular contexts yet large enough to respond vigorously to acoustic fields. Encapsulation efficiency reached approximately 70 to 75 percent, meaning that a substantial fraction of the expensive and toxic drug was successfully sequestered rather than floating free. Most importantly, when ultrasound was applied, more than 80 percent of the encapsulated doxorubicin was released within 40 seconds, while passive release under non-sonicated conditions remained low. That contrast between triggered and untriggered release is the pharmacological heart of the system: it means the drug is effectively caged until the operator decides otherwise.

The biological consequences of that gating were assessed in two cell lines chosen to represent the therapeutic target and the principal off-target risk. In MCF-7 breast cancer cells, the sonicated microbubble formulation—designated DOX-MB plus ultrasound—produced markedly greater cytotoxicity and apoptosis than either free doxorubicin or the microbubbles without ultrasound exposure. The numbers are striking. The apparent IC50, the concentration required to halve cell viability, was 0.0013 micrograms per milliliter for the sonicated formulation, compared with 0.62 micrograms per milliliter for free doxorubicin and 5.44 micrograms per milliliter for the loaded microbubbles left unsonicated. In other words, acoustic activation transformed a relatively weak cytotoxic preparation into one hundreds of times more potent than the free drug against the cancer cells.

A crucial experimental control strengthened the interpretation of those results. The researchers included a Blank MB plus ultrasound condition—microbubbles lacking doxorubicin that were subjected to the same acoustic exposure. This control produced only moderate bioeffects, confirming that cavitation alone does not account for the dramatic killing observed. The enhanced cytotoxicity of the complete system therefore reflects the synergy of two mechanisms working together: mechanical sensitization of the cells by oscillating and collapsing bubbles, and focal delivery of a high local dose of doxorubicin at the moment of collapse. Disentangling these contributions with appropriate controls is precisely the kind of rigor that empirical formulation studies often omit, and it lends credibility to the central claim that the system works as designed.

Just as important as what the bubbles do to cancer cells is what they fail to do to cardiac cells. In H9c2 cardiomyoblast cells, a widely used in vitro model of cardiac toxicity, the microbubble formulation without ultrasound showed reduced baseline toxicity compared with free doxorubicin, with an apparent IC50 of 8.72 micrograms per milliliter versus 5.14 micrograms per milliliter for the free drug. This shift indicates that sequestering doxorubicin within the bubble shell diminishes the drug’s availability to heart cells under normal, non-sonicated conditions—the very scenario that mirrors unintended exposure of cardiac tissue in a patient. The authors are appropriately careful here, describing their selectivity analysis as comparative in vitro indices and noting that the high selectivity value they calculated should be read as a trigger-dependent therapeutic window estimate rather than a conventional matched-condition selectivity index. That caveat reflects a genuine subtlety: the therapeutic window of this system depends on where and when the ultrasound is applied, not merely on intrinsic chemical selectivity.

The technical achievement of the QbD approach deserves particular emphasis. By quantifying how chitosan, palmitic acid, and Pluronic F68 concentrations jointly determine size, loading, and release kinetics, the study converts what is often a craft into a controllable engineering process. A formulator facing regulatory scrutiny can point to a defined design space within which product quality is assured, rather than defending a single recipe arrived at through opaque iteration. This matters especially for ultrasound-responsive systems, where subtle changes in shell composition can profoundly alter acoustic behavior, cavitation thresholds, and therefore both efficacy and safety. The constrained design space identified by the Box–Behnken model balances these competing demands explicitly, holding bubble size near the optimum for acoustic responsiveness while maximizing loading and triggered burst release.

The authors are candid that this work remains an in vitro proof of concept, and the path to the clinic is long. They specify that further acoustic calibration, testing in three-dimensional tumor models, hemocompatibility assessment, pharmacokinetic evaluation, biodistribution analysis, and in vivo tumor-localized ultrasound studies are all required before translational conclusions can be drawn. These are not trivial hurdles. Microbubble behavior in the bloodstream differs substantially from behavior in a culture dish, where bubbles and cells sit in immediate proximity. Blood flow, immune opsonization, bubble aggregation, and the physics of focusing ultrasound through tissue at depth all present real challenges. Hemocompatibility is a particular concern for any particulate system intended for intravascular use, and the interplay between acoustic parameters and tissue heating must be characterized to ensure that the ultrasound itself causes no harm.

Even so, the study offers a compelling demonstration of what rational formulation engineering can accomplish. Doxorubicin that is impotent until switched on by sound, and that spares heart cells when inert, addresses the two central failures of anthracycline chemotherapy in a single design. If subsequent in vivo work confirms that the sharp in vitro potency advantage and the attenuated cardiac exposure translate to living tumors, ultrasound-responsive microbubbles developed through QbD could move from an intriguing laboratory concept toward a genuinely controllable form of chemotherapy—one in which the clinician, not the drug, decides where and when the poison is released.

Subject of Research: Ultrasound-responsive doxorubicin-loaded chitosan microbubbles developed by Quality by Design for targeted breast cancer chemotherapy with reduced cardiac toxicity

Article Title: Ultrasound-responsive doxorubicin microbubbles engineered by QbD: enhanced in vitro anti-breast-cancer efficacy with attenuated cardiac cell toxicity

Article References: Solanki, S., Thota, S., Posa, M. K., Aphale, S., Kaul-Ghanekar, R., Pandey, S., Nagam, S. P., Kamble, S., Kulthe, A., Lalwani, K., Tailor, N. K., Sharma, R., & Solanki, N. (2026). Ultrasound-responsive doxorubicin microbubbles engineered by QbD: enhanced in vitro anti-breast-cancer efficacy with attenuated cardiac cell toxicity. BMC Pharmacology and Toxicology. https://doi.org/10.1186/s40360-026-01229-6

Image Credits: AI Generated

DOI: 10.1186/s40360-026-01229-6

Keywords: doxorubicin, microbubbles, ultrasound-triggered drug delivery, Quality by Design, Box–Behnken design, breast cancer, cardiotoxicity, chitosan, MCF-7 cells, H9c2 cells, controlled release, nanomedicine

The scale of the problem is enormous. According to GLOBOCAN 2022 estimates from the International Agency for Research on Cancer, roughly 20 million new cancer cases occur worldwide each year, and solid tumors account for more than 90 percent of them. Lung, breast, colorectal, prostate, and gastric cancers alone make up 45.8 percent of global incidence. Immune checkpoint inhibitors have delivered durable responses in selected solid tumors, while CAR-T therapy remains largely investigational outside blood cancers. Against this backdrop, NK cell-based immunotherapy has attracted attention for its widely recognized low-risk profile and its potential as an off-the-shelf product.

But solid tumor patients are not the same population as hematologic cancer patients. They tend to be older, with lung and gastrointestinal tumors typically appearing at 60 to 70 years of age, and they carry a heavier burden of cardiovascular comorbidities, including hypertension in 26.0 percent, coronary heart disease in 7.8 percent, and heart failure in 3.3 percent. Prior anthracycline chemotherapy or thoracic radiotherapy often leaves the myocardium in a pre-injured state. Because immune checkpoint inhibitors and CAR-T cells can both trigger cardiovascular toxicity through mechanisms such as cytokine release syndrome, the authors argue that as NK cell strategies expand into solid tumors, their cardiac safety must be comprehensively evaluated before clinical translation proceeds.

NK cells kill through a coordinated set of molecular pathways. The activating receptor NKG2D binds stress-induced ligands such as MICA/B and ULBPs on tumor cells, natural cytotoxicity receptors NKp30, NKp44, and NKp46 recognize tumor-specific antigens, and CD16 mediates antibody-dependent cellular cytotoxicity. Once activated, NK cells release perforin and granzymes to punch pores in target-cell membranes, or trigger apoptosis through death ligands such as FasL and TRAIL. They also secrete interferon-gamma and tumor necrosis factor-alpha to recruit dendritic cells and T cells. Crucially, inhibitory receptors such as KIR and NKG2A recognize MHC class I molecules on healthy tissue, generating tolerance and limiting autoimmune injury.

The tumor microenvironment, however, systematically disarms this arsenal. High concentrations of TGF-beta and IDO suppress NK cell activation and proliferation, while nutrient deprivation, hypoxia, and metabolic byproducts such as lactate and adenosine further erode cytotoxic function. Upregulation of HIF-1alpha in solid tumors induces mitochondrial dysfunction in NK cells and inhibits aerobic glycolysis, causing energy-metabolism failure. Tumor-infiltrating NK cells also upregulate inhibitory checkpoints including PD-1, TIM-3, LAG-3, and TIGIT. Single-cell atlases of breast cancer and hepatocellular carcinoma have identified exhausted NK subsets with high expression of NR4A family genes and KLRC1, and these patients tend to have poorer prognoses.

Three therapeutic strategies aim to reverse this exhaustion. Genetic engineering, most notably chimeric antigen receptor NK cells (CAR-NK), equips NK cells with tumor-antigen-specific receptors; genome-wide CRISPR screening has identified negative regulators such as MED12, ARIH2, and CCNC whose knockout enhances metabolic adaptability, and chemokine receptors such as CXCR4 can be introduced to improve tumor infiltration. Antibody-mediated approaches, including bispecific and trispecific immune-cell engagers that bridge tumor antigens and CD16, as well as novel trispecific nanobodies targeting PD-L1, 4-1BB, and NKG2A, have significantly inhibited tumor growth in preclinical models. Cytokine and metabolic regulation, from IL-15 superagonists to intermittent fasting-induced fatty acid oxidation, offers a third route to restoring NK cell fitness.

The advantages of NK cells over T cells are multidimensional. They recognize cells that have lost MHC class I expression, a common consequence of genomic instability in solid tumors, without needing HLA-restricted antigen presentation. Their low risk of graft-versus-host disease and lack of HLA-matching requirements make them candidates for true off-the-shelf products, in contrast to the individualized CAR-T manufacturing process that takes at least three weeks. NK cells can be derived from cord blood, peripheral blood, induced pluripotent stem cells, or immortalized NK-92 cell lines, enabling standardized scaled production. They also rely more on oxidative phosphorylation than glycolysis, giving them better energy efficiency and fatigue resistance in the hostile tumor microenvironment, and their endogenous interferon-gamma can reprogram tumor-associated macrophages from a tumor-promoting M2 phenotype to an antitumor M1 phenotype.

Safety data so far support this optimism. CAR-NK therapy has shown extremely low incidence of cytokine release syndrome and neurotoxicity, with no definitive reports of grade 3 or higher CRS or immune effector cell-associated neurotoxicity syndrome to date. But the review warns that cardiotoxicity is broadly relevant across immunotherapies, and the safety advantages of NK cells should not be mistaken for absence of risk. Immune checkpoint inhibitor-related cardiotoxicity occurs in roughly 1 to 2 percent of patients with a fatality rate of up to 46 percent, significantly higher than myocardial injury from conventional chemotherapy. In CAR-T treatment, cardiovascular adverse events occur in 20.5 percent of patients, with hypotension and tachycardia presenting as hyperacute events within a median of 6 to 21 days.

The mechanisms of immune-mediated cardiac injury offer a preview of what could go wrong with NK cells. Cytokine release directly damages myocardial mitochondria and disrupts calcium homeostasis through IL-6, TNF-alpha, and interferon-gamma, while activating endothelial cells and inducing microvascular obstruction. Alpha-myosin-specific T cells can drive myocarditis, although TCR sequencing suggests most expanded clones target unknown cardiac antigens, challenging the universality of molecular mimicry. A positive-feedback loop between CCR2-positive macrophages and CD8-positive T cells, mediated by the IL-12b/TNF/interferon-gamma axis, remodels the myocardial immune microenvironment, and NLRP3 inflammasome activation triggers gasdermin-E-dependent pyroptosis and release of mitochondrial DNA that activates the cGAS-STING pathway, causing irreversible tissue damage.

For NK cells specifically, several theoretical risks emerge. Although NK cells secrete less IL-6 and IL-1-beta than activated T cells, and their CRS profile is dominated by interferon-gamma, GM-CSF, and TNF-alpha with typically mild grade 1 to 2 manifestations, even mild CRS can trigger capillary leak syndrome, reducing effective circulating blood volume and myocardial perfusion. TNF-alpha downregulates SERCA2a and promotes ventricular remodeling. In mouse models of acute myocardial infarction, mature NK cells massively infiltrate ischemic myocardium through a CCR2-dependent pathway and their granzyme B directly induces cardiomyocyte apoptosis, while granzyme B can also enter vascular smooth muscle cells without perforin assistance. HER2, a common CAR-NK target antigen, has basal expression in normal cardiomyocytes, and although preclinical studies have not shown toxicity against nonmalignant HER2-positive cells, those conclusions rest on short-term in vitro co-culture that cannot simulate the long-term in vivo immune environment.

Engineered persistence introduces further uncertainty. IL-15 and IL-21 both signal through the JAK1/JAK3-STAT5 axis, which in pressure-overload heart failure models directly drives fibroblast activation and type I collagen deposition. Chronic low-grade IL-15 exposure from CAR-NK cells persisting in vivo for several weeks may induce subclinical interstitial remodeling, and IL-15 has been shown to enhance NK cell glycolysis, potentially creating energy competition with cardiomyocytes that depend on oxidative phosphorylation. Combination with PD-1 inhibitors may amplify interferon-gamma-driven cardiomyocyte iNOS expression and nitric oxide production, while prior anthracycline chemotherapy leaves mitochondria leaking reactive oxygen species that can create a second hit when immunotherapy triggers overlapping autoimmune and inflammatory responses.

The knowledge gaps are stark. No prospective, multicenter study dedicated to the cardiovascular safety of NK cell products has yet been conducted; all reports of arrhythmia, heart failure, or myocarditis are scattered across case reports and secondary endpoint analyses. The CTCAE v5.0 grading system classifies events by absolute values alone, overlooking temporal dynamics and recovery trajectories, so subclinical injuries go underreported. Median follow-up in most NK cell trials is less than two years, while delayed cardiomyopathy and immune-mediated vasculitis often manifest years to more than a decade after treatment. Biomarker cutoffs for troponin and NT-proBNP validated in CAR-T contexts have not been established for CAR-NK, and advanced imaging parameters such as cardiac magnetic resonance T1 values and global longitudinal strain have not been formally incorporated into any NK cell trial.

The review proposes a path forward anchored in cardio-oncology collaboration. Baseline risk stratification should integrate the HFA-ICOS score with solid-tumor-specific factors such as chronic hypoxia and malnutrition, and with clonal hematopoiesis of indeterminate potential, an emerging biomarker associated with IL-6-driven endothelial activation after immune stimulation. Dynamic monitoring should combine high-sensitivity troponin, NT-proBNP, electrocardiography, and cardiac magnetic resonance, with baseline ferritin and IL-6 levels included as validated predictors of CRS-related cardiac dysfunction. The microRNA miR-145, negatively correlated with IL-6 and TNF-alpha, deserves evaluation as a diagnostic and potentially cardioprotective marker. For confirmed immune-related myocarditis, pulse methylprednisolone followed by mycophenolate mofetil maintenance is recommended, while tocilizumab should be reserved for CRS-associated cardiac dysfunction to avoid excessive suppression of antitumor immunity.

Deeper cardiovascular monitoring also raises ethical tensions around economic burden, psychological anxiety, and privacy, requiring a balance between scientific rigor and patient wellbeing. Elevating cardiovascular safety to a core dimension of efficacy evaluation could drive developers to optimize NK cell product design at the source. If those gaps are filled, the authors conclude, NK cell-based immunotherapy could become a more efficient, safer, shorter-cycle, and lower-cost option in solid tumor therapy, but only once its cardiac risks move from inference to evidence.

Subject of Research: NK cell-based immunotherapy for solid tumors and its cardiovascular safety

Article Title: Progress in NK cell-based immunotherapy for solid tumors and an exploration of its cardiovascular safety

Article References: Chen, J., Shen, J., Fu, X., Jiang, M., Liu, R., Qiao, Q., & Hu, Y. (2026). Progress in NK cell-based immunotherapy for solid tumors and an exploration of its cardiovascular safety. Frontiers in Cell and Developmental Biology, 14, Article 1927923. https://doi.org/10.3389/fcell.2026.1927923

Image Credits: AI Generated

DOI: 10.3389/fcell.2026.1927923

Keywords: NK cells, CAR-NK, solid tumors, immunotherapy, cardiotoxicity, cytokine release syndrome, tumor microenvironment, immune checkpoint inhibitors, cardio-oncology, granzyme B, IL-15, myocarditis

The study, published in Frontiers in Cancer Control and Society, drew on four years of data from the National Health Interview Survey (NHIS), an ongoing household survey run by the National Center for Health Statistics since 1957. Researchers led by Robina Josiah Willock of Morehouse School of Medicine analyzed responses from 2,495 women with self-reported breast cancer surveyed between 2019 and 2022, after excluding 250 questionnaires with more than 15 percent missing data. Because the NHIS underwent a comprehensive redesign in 2019, the four survey years are directly comparable, giving the team a nationally representative snapshot of the civilian, non-institutionalized population.

The outcome measure was deliberately broad. A survivor was counted as having cardiovascular disease if she reported a physician-confirmed diagnosis of any one of four conditions: angina, stroke, myocardial infarction, or coronary artery disease. The researchers then split the survivors into five cohorts based on time since diagnosis — less than one year, one to under five years, five to under seven years, seven to under ten years, and ten or more years — and examined how cardiovascular disease prevalence shifted across the survivorship trajectory.

The pattern was striking. Among women diagnosed less than a year earlier, 16.4 percent reported cardiovascular disease, a figure that likely reflects the acute cardiotoxic effects of chemotherapy and radiotherapy during active treatment. Prevalence then fell to 10.5 percent in the one-to-five-year cohort and 11.0 percent in the five-to-seven-year group. But after the seven-year mark, the curve bent sharply upward: 13.8 percent of survivors seven to ten years out reported cardiovascular disease, and among those surviving a decade or longer — the largest cohort, with 1,359 women — the figure reached 19.1 percent, the highest of any group.

That inflection point matters because it lands almost exactly where formal surveillance ends. Current U.S. breast cancer follow-up guidelines call for yearly mammograms for the first five years, physical exams every three to six months during the first three years, and every six to twelve months in years four and five. After year five, survivors are generally told they can return to routine annual care. The American Society of Clinical Oncology does recommend an echocardiogram within six to twelve months after treatment for asymptomatic patients at elevated cardiovascular risk, but beyond that horizon, enhanced cardiac monitoring largely reverts to what is standard for older women who never had cancer.

To understand who was most at risk, the team first ran Wald chi-square tests across seventeen sociodemographic, behavioral, and clinical variables. Thirteen were statistically significant, including employment status, marital status, delayed medical care, diabetes, body mass index, physical activity, cholesterol, hypertension, smoking history, self-rated health, age, and years of survivorship. Insurance status, education, race, and recency of a doctor’s visit were not, and were dropped from the final model. The researchers then built a forward stepwise logistic regression — a technique that adds and removes predictors in turn to produce the most parsimonious set of variables — which showed strong overall fit, with a likelihood ratio of 16.51 and a c-statistic of 0.754.

The regression results quantified the risks with unusual granularity. Women aged 85 and older had 9.75 times the odds of cardiovascular disease compared with those under 45, and women aged 66 to 84 had 4.24 times the odds. Survivors who had delayed medical care for a year or more because of cost or other barriers were 79 percent more likely to report cardiovascular disease. Hypertension nearly doubled the odds, raising them by 106 percent. Perhaps most striking was the weight of self-rated health: women describing their health as fair or poor had 8.05 times the odds of cardiovascular disease compared with those rating their health excellent, while those rating it good or very good had 2.41 times the odds. Women who had smoked at least 100 lifetime cigarettes showed a 28 percent increase in odds, a trend that fell just short of conventional statistical significance.

Some findings defied expectations. Insurance status, education, and race and ethnicity — factors repeatedly implicated in cardiovascular outcomes in prior research — showed no statistically significant association in this sample. The authors caution that this may be an artifact of sampling: roughly 84 percent of respondents without cardiovascular disease and 83 percent of those with it identified as white, leaving the survey underpowered to detect disparities affecting Black, American Indian, and Alaska Native women. That gap is consequential, because Black breast cancer survivors are known to experience higher cardiotoxicity, earlier onset of cardiovascular symptoms, and a 40 percent higher breast cancer mortality rate than white women, while American Indian and Alaska Native women face elevated mortality despite lower incidence.

The biological logic behind the survivorship curve is well established. Anthracyclines and fluoropyrimidines can trigger endothelial dysfunction and severe cardiac damage; methotrexate and fluorouracil have been linked to congestive heart failure; and chest radiotherapy disrupts coronary endothelium, raising the risk of coronary artery disease and subsequent hypertension. Layered on top of treatment effects are the shared risk factors that breast cancer and cardiovascular disease have in common — aging, hypertension, diabetes, hyperlipidemia, smoking, and sedentary lifestyles — which compound over the years as survivors age out of intensive oncology follow-up and back into general primary care.

The authors argue the data demand a paradigm shift: cardiovascular screening for breast cancer survivors should be lifelong and risk-stratified according to treatment type and individual health profiles, not capped at five years. Primary care physicians, who see survivors across the continuum of care, are positioned to lead that effort by managing hypertension, diabetes, and cholesterol with widely available medications, counseling on smoking, nutrition, and physical activity, and coordinating with cardio-oncology specialists when needed. Prior research suggests survivors want exactly this kind of lifestyle guidance but often do not receive it clearly. With the population of long-term survivors growing as treatment improves, the study’s central message is hard to ignore: surviving breast cancer is not the finish line — it is the beginning of a decades-long commitment to the heart.

Subject of Research: Cardiovascular disease risk among female breast cancer survivors in the United States

Article Title: Cardiovascular disease risk among female breast cancer survivors: findings from the National Health Interview Survey (2019–2022)

Article References: Josiah Willock, R., Nabi, S. R., Parks, D. C., Qaseem, B. A., & Miles, M. A. (2026). Cardiovascular disease risk among female breast cancer survivors: findings from the National Health Interview Survey (2019–2022). Frontiers in Cancer Control and Society, 4, Article 1628255. https://doi.org/10.3389/fcacs.2026.1628255

Image Credits: AI Generated

DOI: 10.3389/fcacs.2026.1628255

Keywords: breast cancer, cardiovascular disease, cancer survivors, cardio-oncology, NHIS, hypertension, smoking, social determinants of health, survivorship care, cardiotoxicity, health disparities, logistic regression

The review’s central argument is that toxicity prediction is no longer a single-technique discipline but a layered pipeline in which every stage matters. Traditional safety assessment relies on in vitro assays and animal studies, methods the authors describe as resource-intensive, slow, and limited by interspecies physiological differences that can mask human-specific toxicity. Machine learning and deep learning models, by contrast, can extract complex nonlinear patterns from high-dimensional chemical and biological datasets, enabling rapid screening of large compound libraries during early discovery. This shift builds on decades of quantitative structure-activity relationship (QSAR) modeling, which links chemical structure to biological activity, but modern frameworks go further by learning molecular features directly from data rather than relying on hand-crafted rules.

At the foundation of any predictive model lies the question of how to represent a molecule for computation. The review catalogs the dominant approaches: molecular fingerprints such as MACCS structural keys and extended connectivity fingerprints (ECFPs), which encode substructures as bit strings; numerical descriptors calculated by tools like RDKit, Mordred, PaDEL, and the FDA-developed Mold2; and graph-based representations that treat atoms as nodes and bonds as edges. Graph representations have become especially important because they preserve molecular connectivity and allow graph neural networks (GNNs) to learn directly from structure. More recently, pre-trained chemical language models such as ChemBERTa, SMILES-BERT, MolBERT, and MoLFormer generate learned embeddings that capture richer contextual information than fixed fingerprints ever could.

The authors critically compare conventional machine learning algorithms, including random forests, support vector machines, decision trees, k-nearest neighbors, naive Bayes, XGBoost, and LightGBM, against deep learning architectures spanning deep neural networks, convolutional neural networks, GNNs, and transformer-based models. Their conclusion is deliberately unsentimental: no single architecture consistently wins across toxicity tasks. Conventional methods remain competitive on small to medium datasets with informative descriptors, while deep learning approaches benefit from larger datasets and richer representations. Performance differences reported across studies often reflect variations in dataset composition, endpoint definition, class distribution, and validation strategy rather than genuine algorithmic superiority.

One of the review’s most technically significant sections addresses validation rigor, an issue that quietly undermines many published benchmarks. Random train/test splitting can produce optimistic results when structurally similar compounds or close analogues appear in both sets, a problem compounded by data leakage when preprocessing, feature selection, or hyperparameter optimization occurs before the final split. Scaffold-based, cluster-based, temporal, and independent external validation provide far more honest assessments of generalization to novel chemical space. The authors also stress that accuracy alone is insufficient for imbalanced datasets, where toxic compounds are typically rare; they recommend complementary metrics including sensitivity, specificity, F1-score, balanced accuracy, Matthews correlation coefficient, ROC-AUC, and precision-recall AUC, with calibration considered when predicted probabilities inform risk assessment.

The review then organizes its evidence around five organ-specific toxicity domains, drawing on 40 primary studies published between 2021 and 2026. In respiratory toxicity, random forest models using PubChem fingerprints achieved 93.3% accuracy, while a LightGBM model for chemical lung toxicity reached 86.88% accuracy with a ROC-AUC of 0.931. In cardiotoxicity, transformer models using Morgan fingerprints hit a ROC-AUC of 0.93 for hERG channel interactions, and a multi-view GNN framework called CardiacTox achieved a ROC-AUC of 0.938 for CaV1.2 prediction. Nephrotoxicity models reached a ROC-AUC of 0.93 in consensus approaches, while hepatotoxicity studies reported ResNet18 deep neural networks achieving a test ROC-AUC of 0.958 for drug-induced liver injury. Neurotoxicity studies spanned blood-brain barrier permeability, neuronal cytotoxicity, and acetylcholinesterase inhibition, with hybrid deep learning models reaching ROC-AUC values up to 0.964.

These headline numbers, however, come with caveats the authors refuse to bury. Dataset sizes varied enormously, from 2,670 chemicals in a neurotoxicity study to just 83 breast cancer patients in a radiotherapy cardiotoxicity analysis, and KidneyTox_v1.0 relied on only 565 compounds. Class imbalance, uncertain negative labels, limited chemical-space coverage, and incomplete external validation recurred across all five domains. The authors emphasize that a higher ROC-AUC in one organ domain does not indicate a superior modeling approach, because biological endpoints, dataset characteristics, and prediction tasks differ fundamentally across systems. Hepatotoxicity studies typically target drug-induced liver injury, cardiotoxicity studies focus on specific molecular targets like hERG and CaV1.2, and neurotoxicity encompasses heterogeneous endpoints from blood-brain barrier permeability to mammalian neurotoxicity.

Interpretability receives equally critical treatment. Explainable artificial intelligence techniques such as SHAP, attention mechanisms, saliency methods, and structural-alert identification can reveal which molecular features drive a prediction, but the authors draw a sharp line between explaining a model and establishing biological causation. High SHAP values or atom-level attribution maps identify features associated with a prediction without proving those features cause the toxic effect, and attribution results can shift with molecular representation, correlated descriptors, and model architecture. True mechanistic interpretation requires independent evidence from experimental validation, target-interaction data, toxicogenomics, pathway analysis, or adverse outcome pathways. The review also highlights the applicability domain concept, which defines the region of chemical space where a model can be trusted; predictions for compounds far from training data may be unreliable even when internal performance metrics look impressive.

On the regulatory front, the authors argue that strong retrospective performance alone cannot establish suitability for real-world safety assessment. Regulatory confidence depends on independent external validation, clearly defined endpoints, transparent and reproducible workflows, applicability-domain assessment, uncertainty evaluation, and adequate documentation of input data, preprocessing, algorithms, and known limitations. The review catalogs major toxicity databases including SIDER, FAERS, ADReCS, Pneumotox, PubChem, DrugBank, ChEMBL, ICE, LINCS L1000, and LiverTox, noting that clinical adverse-event sources differ fundamentally from experimental toxicity resources and should not be treated as interchangeable. Data quality, endpoint harmonization, and duplicate removal emerge as prerequisites before any model development begins.

Looking forward, the review identifies active learning and federated learning as strategies to overcome limited labeled data, foundation models as a path to stronger molecular representation, and multimodal learning as a way to combine molecular graphs, SMILES strings, structural images, and spectroscopic information. The authors call for improved negative-data construction, assay and endpoint harmonization, causal and mechanistic modeling, and prospective validation to build tools that are reliable, interpretable, and generalizable enough for regulatory applications. Their overarching message is measured but firm: artificial intelligence has demonstrated competitive and sometimes improved predictive performance in toxicology, but it should not be considered inherently superior to conventional methods. The technology’s real value depends on disciplined data curation, rigorous validation, and honest acknowledgment of where predictions can and cannot be trusted.

Subject of Research: Artificial intelligence methods for predicting chemical and drug toxicity across organ-specific endpoints

Article Title: A review on advances in chemical compound toxicology prediction

Article References: Hagag, A., Elsayed, N. A., & Abdelbaky, I. (2026). A review on advances in chemical compound toxicology prediction. Frontiers in Bioinformatics, 6, Article 1974935. https://doi.org/10.3389/fbinf.2026.1974935

Image Credits: AI Generated

DOI: 10.3389/fbinf.2026.1974935

Keywords: toxicity prediction, machine learning, deep learning, graph neural networks, QSAR, hepatotoxicity, cardiotoxicity, nephrotoxicity, neurotoxicity, explainable AI, drug safety, molecular fingerprints

At the center of this emerging field sits a deceptively simple question: how do you test whether a cancer drug will disrupt the heartbeat without putting a patient in danger? The answer, for now, lies in the laboratory. Two categories of harm dominate the concern. The first is arrhythmia, the dangerous derangement of the heart’s electrical rhythm, which in its worst form can trigger sudden cardiac arrest. The second is contraction dysregulation, in which the mechanical beating of heart cells weakens or desynchronizes, foreshadowing the pump failure clinicians know as cardiomyopathy. Both can be modeled in vitro, in dishes of beating heart cells, but the accuracy of those models depends entirely on the tools used to interrogate them, and a recent review published in Frontiers in Electronics argues that those tools are overdue for an upgrade.

The current benchmark for preclinical rhythm safety testing is the Comprehensive in vitro Proarrhythmia Assay, or CiPA, an initiative launched in 2013 after a string of drugs were withdrawn from the market for causing fatal arrhythmias. CiPA replaced the old, blunt instruments of cardiac safety pharmacology with a tiered strategy that combines in vitro measurements, computer simulations, and clinical evidence to evaluate proarrhythmic risk with far greater specificity and sensitivity than legacy assays. Its scope deliberately stretches across a broad range of pharmaceutical compounds, and that includes chemotherapeutics, making it the natural starting point for anyone trying to predict how a cancer drug will behave in the electrical circuitry of the heart.

Under CiPA, the recommended in vitro toolbox includes several distinct technologies for measuring the electrical activity of heart cells. Transmembrane potential can be recorded directly through patch clamp techniques, including their automated, high-throughput variants, which offer exquisite sensitivity to the ion channel currents that drive each heartbeat. Impedance measurements track how cells deform as they contract, providing a window into mechanical function. Voltage-sensitive optical assays, including voltage indicator dyes and genetically encoded voltage indicators, convert electrical activity into light that cameras can capture across an entire cell culture at once. Alongside these, microelectrode arrays occupy a privileged position, reading out the extracellular electrical field generated by spontaneously beating cardiomyocytes through dozens or hundreds of embedded electrodes.

Critically, CiPA also specifies what the cells should be. The framework recommends pairing these measurement techniques with human induced pluripotent stem cell derived cardiomyocytes, abbreviated hiPSC-CMs, cells that begin as a patient’s own skin or blood cells before being reprogrammed into an embryonic-like state and coaxed into becoming beating heart muscle. This matters enormously for precision cardio-oncology, because hiPSC-CMs can be derived from individual cancer patients, meaning a cardiologist could one day test a chemotherapy regimen against a cellular replica of that specific patient’s heart before committing to a treatment plan. The combination of human genetics and laboratory throughput is what gives the modern approach its promise, and its urgency, as immunotherapies with novel cardiac side effects enter widespread clinical use.

Herein lies the gap the review identifies. While CiPA offers a mature framework for drug-induced arrhythmia, there are currently no guidelines in place for the in vitro assessment of cancer treatment induced arrhythmia specifically, no standardized protocols for evaluating contraction dysregulation caused by oncology drugs, and no agreed-upon methods for testing cardiotoxicity arising from cell-based cancer therapies, a rapidly growing class of treatments including engineered immune cells. Cancer therapy is not simply another branch of general pharmacology; chemotherapeutic and immunotherapeutic agents act through mechanisms that differ fundamentally from conventional small-molecule drugs, and the patient populations receiving them, the very young and the very old, have cardiac physiology that standard testing may not capture. Without standardized assays, each laboratory improvises, results are difficult to compare, and genuinely risky therapies may pass through the cracks.

The review’s central argument is that microelectrode arrays, or MEAs, are the technology best positioned to close that gap. A microelectrode array is exactly what the name implies: a dish, often glass or a flexible polymer substrate, embedded with a grid of microscopic electrodes that sit beneath or around a culture of cardiomyocytes. As the cells beat spontaneously, each depolarization generates an extracellular electrical signal that the electrodes record in real time, producing a continuous stream of data on firing rate, beat-to-beat timing, conduction velocity across the culture, and the emergence of irregular rhythms that signal proarrhythmic danger. Because the measurement is noninvasive, the same culture can be monitored for days or weeks, allowing chronic exposure studies that mimic real-world treatment courses rather than single-dose snapshots.

What elevates MEAs from useful to potentially transformative, the authors contend, is their capacity for simultaneous, multiparameter monitoring. Modern MEA platforms can track the electrophysiological activity of the culture, its contractile behavior, and morphological changes in the cells themselves, all within a single experiment. That matters because cancer treatment cardiotoxicity rarely announces itself through one channel alone. A drug might subtly slow conduction before it destabilizes rhythm, or impair contractile force while the electrical waveform still looks superficially normal. An assay that measures only one parameter can miss the early warning signs, whereas a platform that watches electricity, mechanics, and cell structure at once can build a composite picture of cardiac health, catching deterioration earlier and characterizing its mechanism more completely. Applied to both chemotherapeutic and immunotherapeutic agents, this integrated approach could form the backbone of the standardized testing protocols that cardio-oncology currently lacks.

The trajectory of the technology reflects its own history. Microelectrode arrays were born in classical electrophysiology, where they served for decades as a workhorse for recording neuronal and cardiac activity in slices and cultures. Their migration into cardiotoxicity testing represents both a technical and conceptual evolution: from observing what heart cells do naturally, to predicting what drugs will do to them. Combined with automated analysis, increasingly sophisticated human cell models, and the patient-specific potential of hiPSC-CMs, MEAs are evolving from a research instrument into a screening platform that could sit at the intersection of oncology and cardiology clinics, evaluating proposed cancer treatments against living human heart tissue before a single patient is exposed.

The stakes of getting this right are difficult to overstate. As cancer survival continues to improve, the population of long-term survivors living with treatment-damaged hearts grows in parallel, and pediatric patients cured of leukemia today may face decades of cardiovascular consequences tomorrow. A validated, standardized, in vitro pipeline for detecting cancer treatment induced arrhythmia and contraction dysregulation before clinical exposure would not merely protect future patients; it could also rescue promising oncology drugs whose cardiac liabilities are identifiable and manageable if caught early. The review’s message is that the tools exist, the cellular models exist, and the clinical need is urgent. What remains is the regulatory and scientific work of standardization, turning the humming electrodes of the microelectrode array into the sentinel that stands guard between a cancer cure and the heart that must carry the patient through it.

Subject of Research: In vitro assessment of cancer treatment-induced cardiotoxicity using microelectrode arrays

Article Title: Microelectrode arrays: from electrophysiology to integrated cancer treatment induced cardiotoxicity assessment

Article References: Karami, N., Knafl, S., Wanzenboeck, H. D., & Prado-López, S. (2026). Microelectrode arrays: from electrophysiology to integrated cancer treatment induced cardiotoxicity assessment. Frontiers in Electronics, 7, Article 1886715. https://doi.org/10.3389/felec.2026.1886715

Image Credits: AI Generated

DOI: 10.3389/felec.2026.1886715

Keywords: microelectrode arrays, cardiotoxicity, cardio-oncology, chemotherapy, immunotherapy, arrhythmia, CiPA, hiPSC-derived cardiomyocytes, patch clamp, contractility, drug screening, precision medicine